HM2-16F

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameHM2-16F
Drug Alias Nameurokinase plasminogen activator inhibitors (Fuzhou University)BB2-50FHM2-16F
ClassificationSmall molecules
Mechanisms of ActionUrokinase plasminogen activator inhibitors
TargetsUrokinase plasminogen activator
Therapy Area/IndicationsNeoplasmsBacterial Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia and New ZealandNew Zealand +[4] 
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesFuzhou University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of New South WalesMemorial Sloan Kettering Cancer CenterUniversity Of Otago +[5] 
Active IndicationsN/A
Inactive IndicationsNeoplasmsBacterial Infections

Other Information

ATC CodeN/A
Related LinksN/A